Systemic evaluation of the relationship between psoriasis, psoriatic arthritis and osteoporosis: observational and Mendelian randomisation study

Objectives and methods With 432 513 samples from UK Biobank dataset, multivariable linear/logistic regression were used to estimate the relationship between psoriasis/psoriatic arthritis (PsA) and estimated bone mineral density (eBMD)/osteoporosis, controlling for potential confounders. Here, confounders were set in three ways: model0 (including age, height, weight, smoking and drinking), model1…

Read the full article here

Source: Annals of the Rheumatic Diseases

Categories: Latest Headlines, Rheumatology

Tags: Arthritis, osteoporosis

Tweets with this article

ARD & RMD Open

The association between psoriatic #arthritis and #osteoporosis was not genetically determined but secondary in this study using with 432 513 samples from the UK Biobank https://t.co/PeFojYbGqi

Disease flares with baricitinib dose reductions and development of flare criteria in patients with CANDLE/PRAAS

Objectives Patients with chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature/proteasome-associated autoinflammatory syndrome (CANDLE/PRAAS) respond to the janus kinase inhibitor 1/2 inhibition with baricitinib…

ARD & RMD Open April 25, 2024

What rheumatologists need to know about mRNA vaccines: current status and future of mRNA vaccines in autoimmune inflammatory rheumatic diseases

Messenger RNA (mRNA) vaccines as a novel vaccine platform offer new tools to effectively combat both emerging and existing pathogens which were previously not possible.…

ARD & RMD Open April 24, 2024

Interrupting an IFN-γ-dependent feedback loop in the syndrome of pyogenic arthritis with pyoderma gangrenosum and acne

Objectives To study the molecular pathogenesis of PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome, a debilitating hereditary autoinflammatory disease caused by dominant mutation in…

ARD & RMD Open April 22, 2024

Comorbidity clusters in patients with rheumatoid arthritis identify a patient phenotype with a favourable prognosis

Objectives We aimed to cluster patients with rheumatoid arthritis (RA) based on comorbidities and then examine the association between these clusters and RA disease activity…

ARD & RMD Open April 20, 2024

Potential and pitfalls of repurposing the CAR-T cell regimen for the treatment of autoimmune disease

Chimeric antigen receptors (CARs) are synthetic proteins designed to direct an immune response toward a specific target and have been used in immunotherapeutic applications through…

ARD & RMD Open April 19, 2024

Shift in perspective: autoimmunity protecting against rheumatoid arthritis

A hallmark of rheumatoid arthritis (RA) is the increased levels of autoantibodies preceding the onset and contributing to the classification of the disease. These autoantibodies,…

ARD & RMD Open April 18, 2024

Disentangling the riddle of systemic lupus erythematosus with antiphospholipid syndrome: blood transcriptome analysis reveals a less-pronounced IFN-signature and distinct molecular profiles in venous versus arterial events

Introduction Systemic lupus erythematosus with antiphospholipid syndrome (SLE-APS) represents a challenging SLE endotype whose molecular basis remains unknown. Methods We analysed whole-blood RNA-sequencing data from…

ARD & RMD Open April 16, 2024

Combined inhibition of IL-1, IL-33 and IL-36 signalling by targeting IL1RAP ameliorates skin and lung fibrosis in preclinical models of systemic sclerosis

Background The interleukin (IL)-1 receptor accessory protein (IL1RAP) is an essential coreceptor required for signalling through the IL-1, IL-33 and IL-36 receptors. Here, we investigate…

ARD & RMD Open April 15, 2024

Risk of cardiovascular disease with high-dose versus low-dose use of non-steroidal anti-inflammatory drugs in ankylosing spondylitis

Objective To investigate the risk of cardiovascular disease (CVD) associated with increasing dose of a non-steroidal anti-inflammatory drug (NSAID) in patients with ankylosing spondylitis (AS).…

ARD & RMD Open April 12, 2024

Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry

Objectives To compare the safety of Janus kinase inhibitors (JAKi) with that of tumour necrosis factor inhibitors (TNFi) and determine drug persistence among patients with…

ARD & RMD Open April 11, 2024

Related Articles